Pfizer: Defensive Yield + Pipeline Upside Merit a Buy as Policy Risk Eases
Pfizer is trading at a reasonable valuation with a 6.7% yield, solid free cash flow and manageable leverage. Political talk of aggressive drug pricing reform has cooled, and the company’s pipeline (notably pneumococcal vaccines) plus accretive M&A optionality give a clear path to upside. We recommend a mid-term long with an entry at current levels,…